n.a. (DSCI)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Derma Sciences Inc. Stock Upgraded By TheStreet Ratings (DSCI)

Derma Sciences Inc. Stock Upgraded By TheStreet Ratings (DSCI)

Derma (Nasdaq:DSCI) has been upgraded by TheStreet Ratings from a sell to hold.

Biotech Stock Mailbag: Derma Sciences

Biotech Stock Mailbag: Derma Sciences

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Derma Sciences Reports Positive Top-Line Results From DSC127 Phase 2 Trial In Patients With Diabetic Foot Ulcers

Derma Sciences Reports Positive Top-Line Results From DSC127 Phase 2 Trial In Patients With Diabetic Foot Ulcers

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced positive results from its Phase 2 clinical trial with DSC127 in patients with diabetic ...

Derma Sciences To Hold Conference Call To Discuss Results From Phase 2 DSC127 Trial In Diabetic Foot Ulcers February 3

Derma Sciences To Hold Conference Call To Discuss Results From Phase 2 DSC127 Trial In Diabetic Foot Ulcers February 3

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, will issue a news release announcing top-line efficacy results from its Phase 2 trial with DSC127 in...

Derma Sciences Launches Advanced Wound Care ELearning Portal For Clinicians

Derma Sciences Launches Advanced Wound Care ELearning Portal For Clinicians

Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces the launch of a new eLearning Portal to provide clinicians with valuable educational programs to...

Derma Sciences To Present At The Fourth Annual Maxim Group Growth Conference

Derma Sciences To Present At The Fourth Annual Maxim Group Growth Conference

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that the company will be participating in the Fourth Annual Maxim Group Growth...

Derma Sciences Reports Third Quarter Net Sales Up 17%, Advanced Wound Care Sales Up 38%

Derma Sciences Reports Third Quarter Net Sales Up 17%, Advanced Wound Care Sales Up 38%

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and nine months ended September 30, 2010.

Derma Sciences Announces Third Quarter 2010 Results Conference Call

Derma Sciences Announces Third Quarter 2010 Results Conference Call

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, will hold a conference call on November 12, 2010 to discuss the financial results for the third quarter ...

Derma Sciences Awarded $244,479 From U.S. Government Under The Patient Protection And Affordable Care Act

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that it has been awarded a research and development grant of $244,479 from the U.

Derma Sciences To Complete Enrollment In DSC127 Phase 2 Wound Healing Trial This Month

Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that patient screening in its DSC127 Phase 2 trial in diabetic foot ulcer healing will be...

Derma Sciences To Present At The Rodman & Renshaw 12th Annual Global Investment Conference

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that the company will be participating in the Rodman & Renshaw 12th Annual Global...

Derma Sciences Novel XTRASORB® HCS Dressings Receive Federal Reimbursement Codes; Join Foam And Classic Dressings For Complete Coverage Of Product Category

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that all five products in its novel line of XTRASORB® HCS Dressings have received...

Derma Sciences Second Quarter Results Feature Net Sales Up 14%; Advanced Wound Care Sales Up 47%

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and six months ended June 30, 2010.

Derma Sciences Announces Second Quarter 2010 Results Conference Call

Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, will hold a conference call on August 13, 2010 to discuss the financial results for the second quarter ...

Derma Sciences Submits 510(k) Application For MEDIHONEY Gel, Reaches Goal Of 20-Person U.S. Field Sales Force

Derma Sciences Submits 510(k) Application For MEDIHONEY Gel, Reaches Goal Of 20-Person U.S. Field Sales Force

Derma Sciences, Inc. (NASDAQ: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces the achievement of regulatory and commercial milestones.

Derma Sciences Added To Russell Microcap Index

Derma Sciences Added To Russell Microcap Index

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that the Company’s common stock has been added to the Russell Microcap® Index ...

Derma Sciences Announces Issuance Of Second U.S. Patent Related To MEDIHONEY Alginate Dressing

Derma Sciences Announces Issuance Of Second U.S. Patent Related To MEDIHONEY Alginate Dressing

Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that the U.

Derma Sciences Licenses Worldwide Medihoney Rights

Derma Sciences licenses worldwide Medihoney product rights from Comvita New Zealand